13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001281446
Total reported value
$529.1M
$529.1M
26 檔
14.7%
According to the latest 13F quarterly dataset, Great Point Partners LLC managed an equity portfolio of $529.1M at the end of Q4 2024, spanning 26 distinct U.S. exchange-listed positions.
In Q4 2024, Great Point Partners LLC adopted a defensive or profit-taking posture, trimming 12 positions and completely liquidating 8 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 8.32% | — | +98.04% | |
| 2 | CYTK | Cytokinetics Inc | Stock-Healthcare | 7.98% | — | +13.92% | |
| 3 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 7.13% | -3.12% | EXIT | |
| 4 | VRDN | Viridian Therapeutics Inc | Stock-Other | 6.78% | — | — | |
| 5 | PLRX | Pliant Therapeutics Inc | Stock-Other | 6.55% | — | -44.77% | |
| 6 | ABVX | Abivax Sa-adr | Stock-Other | 5.69% | +15.22% | NEW | |
| 7 | DVAX | Dynavax Technologies CORP | Stock-Other | 5.18% | — | -35.15% | |
| 8 | NGNE | Neurogene Inc | Stock-Other | 4.77% | -0.23% | -55.91% | |
| 9 | EOLS | Evolus Inc | Stock-Other | 4.66% | — | -23.46% | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 4.53% | — | — | |
| 11 | ✓ | Stock-Other | 4.11% | — | +28.29% | ||
| 12 | ✓ | Zura Bio LTD | Stock-Other | 3.73% | -1.07% | -2.86% | |
| 13 | AUTL | Autolus Therapeutics PLC | Stock-Other | 3.33% | — | +7.02% | |
| 14 | JSPR | Jasper Therapeutics Inc | Stock-Other | 3.25% | — | — | |
| 15 | ✓ | Merus N V | Stock-Other | 3.13% | — | -36.76% | |
| 16 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.83% | — | — | |
| 17 | ✓ | Helix Acquisition CORP Ii | Stock-Other | 2.47% | — | — | |
| 18 | UPB | Upstream Bio Inc | Stock-Other | 2.32% | — | — | |
| 19 | CNTX | Context Therapeutics Inc | Stock-Other | 2.32% | -1.35% | EXIT | |
| 20 | VYGR | Voyager Therapeutics Inc | Stock-Other | 2.21% | — | -13.88% | |
| 21 | ORKA | Oruka Therapeutics Inc | Stock-Other | 2.09% | +1.23% | -55.54% | |
| 22 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 1.90% | — | — | |
| 23 | RZLT | Rezolute Inc | Stock-Other | 1.44% | +0.27% | — | |
| 24 | PMNEUR | Promis Neurosciences Inc | Stock-Other | 1.18% | — | -5.22% | |
| 25 | OPTNUSD | Optinose Inc | Stock-Other | 1.17% | — | — | |
| 26 | URGN | UroGen Pharma Ltd. | Stock-Other | 0.94% | — | -75.24% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | IONS | Ionis Pharmaceuticals Inc | +5.3% | +98.04% | Add |
| 2 | XENE | Xenon Pharmaceuticals Inc | +4.5% | NEW | New buy |
| 3 | ✓ | +3.1% | +28.29% | Add | |
| 4 | CYTK | Cytokinetics Inc | +3.1% | +13.92% | Add |
| 5 | 4XC1 | Kalvista Pharmaceuticals Inc | +2.7% | +37.51% | Add |
| 6 | UPB | Upstream Bio Inc | +2.3% | NEW | New buy |
| 7 | MREO | Mereo Biopharma Group Pl-adr | +1.9% | NEW | New buy |
| 8 | VRDN | Viridian Therapeutics Inc | +1.8% | — | Unchanged |
| 9 | JSPR | Jasper Therapeutics Inc | +1.5% | — | Unchanged |
| 10 | RZLT | Rezolute Inc | +1.4% | NEW | New buy |
| 11 | OPTNUSD | Optinose Inc | +1.2% | NEW | New buy |
| 12 | ✓ | Helix Acquisition CORP Ii | +0.9% | — | Unchanged |
| 13 | DVAX | Dynavax Technologies CORP | +0.8% | -35.15% | Trim |
| 14 | DNTH | Dianthus Therapeutics Inc | +0.6% | — | Unchanged |
| 15 | VYGR | Voyager Therapeutics Inc | +0.6% | -13.88% | Trim |
| 16 | AUTL | Autolus Therapeutics PLC | +0.3% | +7.02% | Add |
| 17 | PLRX | Pliant Therapeutics Inc | +0.3% | -44.77% | Trim |
| 18 | PMNEUR | Promis Neurosciences Inc | +0.2% | -5.22% | Trim |
| 19 | ✓ | Zura Bio LTD | -0.2% | -2.86% | Trim |
| 20 | CLYM | Climb Bio Inc | -0.4% | EXIT | Sold out |
| 21 | ✓ | Merus N V | -0.6% | -36.76% | Trim |
| 22 | VTGN | Vistagen Therapeutics Inc | -0.6% | EXIT | Sold out |
| 23 | EOLS | Evolus Inc | -0.9% | -23.46% | Trim |
| 24 | RNAC | Cartesian Therapeutics Inc | -1% | EXIT | Sold out |
| 25 | TCRX | Tscan Therapeutics Inc | -1.5% | EXIT | Sold out |
| 26 | ABVX | Abivax Sa-adr | -1.5% | -22.56% | Trim |
| 27 | ORKA | Oruka Therapeutics Inc | -1.6% | -55.54% | Trim |
| 28 | CNTX | Context Therapeutics Inc | -1.7% | -32.46% | Trim |
| 29 | URGN | UroGen Pharma Ltd. | -1.9% | -75.24% | Trim |
| 30 | OTLK | Outlook Therapeutics Inc | -2% | EXIT | Sold out |
| 31 | ✓ | Optinose Inc | -2.5% | EXIT | Sold out |
| 32 | OLMA | Olema Pharmaceuticals Inc | -3.5% | EXIT | Sold out |
| 33 | ACLXGBX | Arcellx Inc | -4.9% | EXIT | Sold out |
| 34 | NGNE | Neurogene Inc | -7.6% | -55.91% | Trim |
According to official SEC Form 13F filings, Great Point Partners LLC reported a total U.S. public equity portfolio value of $529.1M across 26 disclosed positions in Q4 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including IONS, CYTK, 4XC1) accounted for 14.7% of total reported equity market value during Q4 2024.
Top New Position Initiated
XENE
市值: $9.6M
Top Position Liquidated / Trimmed
ACLXGBX
前期市值: $16.7M
During Q4 2024, Great Point Partners LLC's top holdings by market value included IONS (8.3%)、CYTK (8.0%)、4XC1 (7.1%). The largest single position, IONS, represented 8.3% of total portfolio value.
In Q4 2024, Great Point Partners LLC made 30 total portfolio adjustments, initiating 5 new buys, adding to 5 positions, trimming 12 holdings, and fully liquidating 8 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.